Table 1.

Baseline patient characteristics.

	Standard Arm (n = 115)	Tosedostat 120 mg (n = 116)	Total
Sex
M	72 (63%)	76 (66%)	148 (64%)
F	43 (37%)	40 (34%)	83 (36%)
Age groups
≤70 years	72 (63%)	64 (55%)	136 (59%)
>70 years	43 (37%)	52 (45%)	95 (41%)
Age
Mean; SD	69.9; 3.26	70.7; 3.75	70.3; 3.53
Median; range	69; 66–79	70; 66–81	70; 66–81
WHO performance
0	63 (55%)	54 (47%)	117 (51%)
1	43 (37%)	50 (43%)	93 (40%)
2	8 (7%)	11 (9%)	19 (8%)
NA	1 (1%)	1 (1%)	2 (1%)
Diagnosis
MDS	15 (13%)	16 (14%)	31 (13%)
AML	100 (87%)	100 (86%)	200 (87%)
Prior HM
No	109 (95%)	106 (93%)	215 (94%)
Yes	6 (5%)	8 (7%)	14 (6%)
AML risk group (acc. to HOVON 103 protocol) *
Good	8 (7%)	2 (2%)	10 (4%)
Intermediate	35 (30%)	39 (34%)	74 (32%)
Poor	60 (52%)	57 (49%)	117 (51%)
Very poor	12 (10%)	18 (16%)	30 (13%)
NPM1 mutation
Neg	51 (44%)	53 (46%)	104 (45%)
Pos	19 (17%)	19 (16%)	38 (16%)
NA	45 (39%)	44 (38%)	89 (39%)
FLT3ITD
Neg	60 (52%)	67 (58%)	127 (55%)
Pos	12 (10%)	7 (6%)	19 (8%)
NA	43 (37%)	42 (36%)	85 (37%)
FLT3 TKD835
Neg	33 (29%)	31 (27%)	64 (28%)
Pos	2 (2%)	3 (3%)	5 (2%)
NA	80 (70%)	82 (71%)	162 (70%)
EVI1 overexpression
Neg	65 (57%)	61 (53%)	126 (55%)
Pos	8 (7%)	11 (9%)	19 (8%)
NA	42 (37%)	44 (38%)	86 (37%)
CEBPA DM
Neg	63 (55%)	68 (59%)	131 (57%)
Pos	4 (3%)	2 (2%)	6 (3%)
NA	48 (42%)	46 (40%)	94 (41%)
FLT3ITD × NPM1 mutation
Pos × Pos	9 (8%)	5 (4%)	14 (6%)
Pos × neg	3 (3%)	1 (1%)	4 (2%)
Neg × Pos	10 (9%)	14 (12%)	24 (10%)
Neg × Neg	47 (41%)	50 (43%)	97 (42%)
NA	46 (40%)	46 (40%)	92 (40%)

HM: Hematological Malignancy; NA: Not available; * see Table S1.